These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30837588)

  • 21. Effects of conformational alteration induced by D-/L-isonucleoside incorporation in siRNA on their stability in serum and silencing activity.
    Huang Y; Chen Z; Chen Y; Zhang H; Zhang Y; Zhao Y; Yang Z; Zhang L
    Bioconjug Chem; 2013 Jun; 24(6):951-9. PubMed ID: 23682837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction and History of the Chemistry of Nucleic Acids Therapeutics.
    Gait MJ; Agrawal S
    Methods Mol Biol; 2022; 2434():3-31. PubMed ID: 35213007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
    Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
    Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
    Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
    Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular dynamics simulation and binding energy calculation for estimation of oligonucleotide duplex thermostability in RNA-based therapeutics.
    Shen L; Johnson TL; Clugston S; Huang H; Butenhof KJ; Stanton RV
    J Chem Inf Model; 2011 Aug; 51(8):1957-65. PubMed ID: 21702481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvements to Hybridization-Ligation ELISA Methods to Overcome Bioanalytical Challenges Posed by Novel Oligonucleotide Therapeutics.
    Haegele JA; Boyanapalli R; Goyal J
    Nucleic Acid Ther; 2022 Aug; 32(4):350-359. PubMed ID: 35404142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides.
    Pendergraff H; Schmidt S; Vikeså J; Weile C; Øverup C; W Lindholm M; Koch T
    Nucleic Acid Ther; 2020 Feb; 30(1):4-13. PubMed ID: 31618108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and Opportunities for Nucleic Acid Therapeutics.
    Corey DR; Damha MJ; Manoharan M
    Nucleic Acid Ther; 2022 Feb; 32(1):8-13. PubMed ID: 34931905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.
    Vester B; Wengel J
    Biochemistry; 2004 Oct; 43(42):13233-41. PubMed ID: 15491130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA).
    Jepsen JS; Pfundheller HM; Lykkesfeldt AE
    Oligonucleotides; 2004; 14(2):147-56. PubMed ID: 15294077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA helicase A is not required for RISC activity.
    Liang XH; Crooke ST
    Biochim Biophys Acta; 2013 Oct; 1829(10):1092-101. PubMed ID: 23895878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
    Orum H; Wengel J
    Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative Quantification of siRNA Strand Loading into Ago2 for Design of Highly Active siRNAs.
    Angart PA; Adu-Berchie K; Carlson RJ; Vocelle DB; Chan C; Walton SP
    Methods Mol Biol; 2019; 1974():41-56. PubMed ID: 31098994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications.
    Veedu RN; Wengel J
    Chem Biodivers; 2010 Mar; 7(3):536-42. PubMed ID: 20232325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NMR studies of fully modified locked nucleic acid (LNA) hybrids: solution structure of an LNA:RNA hybrid and characterization of an LNA:DNA hybrid.
    Nielsen KE; Rasmussen J; Kumar R; Wengel J; Jacobsen JP; Petersen M
    Bioconjug Chem; 2004; 15(3):449-57. PubMed ID: 15149171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of stability and activity of siRNA by terminal substitution with serinol nucleic acid (SNA).
    Kamiya Y; Takai J; Ito H; Murayama K; Kashida H; Asanuma H
    Chembiochem; 2014 Nov; 15(17):2549-55. PubMed ID: 25233814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA.
    Frieden M; Christensen SM; Mikkelsen ND; Rosenbohm C; Thrue CA; Westergaard M; Hansen HF; Ørum H; Koch T
    Nucleic Acids Res; 2003 Nov; 31(21):6365-72. PubMed ID: 14576324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of multiple bioanalytical assay platforms for the quantitation of siRNA therapeutics.
    Agrawal K; Calliste LK; Ji S; Xu S; Ayers SA; Jian W
    Bioanalysis; 2024; 16(13):651-667. PubMed ID: 39254503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LC-MS quantification of oligonucleotides in biological matrices with SPE or hybridization extraction.
    Sips L; Ediage EN; Ingelse B; Verhaeghe T; Dillen L
    Bioanalysis; 2019 Nov; 11(21):1941-1954. PubMed ID: 31829054
    [No Abstract]   [Full Text] [Related]  

  • 40. LC-TOF-MS methods to quantify siRNAs and major metabolite in plasma, urine and tissues.
    Ramanathan L; Shen H
    Bioanalysis; 2019 Nov; 11(21):1983-1992. PubMed ID: 31829057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.